Nasdaq · Healthcare
AGIOS PHARMACEUTICALS, INC. (AGIO)
As-reported financials and recent SEC filings for AGIOS PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$54.0M
Net income
$-412.8M
Net margin
—
Diluted EPS
$-7.12
ROE
-34.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 |
| Gross profit | $47.7M | $32.3M | $23.9M | $12.5M | — |
| Operating income | $-472.1M | $-425.7M | $-391.5M | $-389.0M | $-378.4M |
| Net income | $-412.8M | $673.7M | $-352.1M | $-231.8M | $1.60B |
| Diluted EPS | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →SCHEDULE 13G2026-07-02
View on EDGAR →1442026-07-01
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →Largest Healthcare peers
Go deeper on AGIO
Search AGIOS PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.